Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.48 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329422 | 0.78 | SLC6A4 (0.59) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| Hydrochloric Acid SCHEMBL6331922 | 0.77 | SLC6A4 (0.60) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6330488 | 0.75 | NOS2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6746298 | 0.75 | NOS2 (0.48) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| SCHEMBL6330495 | 0.74 | NOS2 (0.48) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 | |
| Hydrochloric Acid SCHEMBL6752544 | 0.74 | NOS2 (0.48) | NOS2CYP2D6SLC6A2SLC6A4S1PR1 | |
| SCHEMBL6746314 | 0.74 | NOS2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4S1PR1 | |
| SCHEMBL6746312 | 0.74 | NOS2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4S1PR1 | |
| SCHEMBL6190024 | 0.74 | SLC6A2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4S1PR1 | |
| SCHEMBL6187815 | 0.73 | SLC6A2 (0.46) | NOS2CYP2D6SLC6A2SLC6A4BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | claimed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | NOS2 6/4885CYP2D6 48/4885SLC6A2 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.